Drug Insight: new antiemetics in the management of chemotherapy-induced nausea and vomiting

This publication has 14 references indexed in Scilit:

• Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy
  Supportive Care in Cancer, 2004
• Incidence of chemotherapy‐induced nausea and emesis after modern antiemetics
  Cancer, 2004
• Improved prevention of moderately emetogenic chemotherapy‐induced nausea and vomiting with palonosetron, a pharmacologically novel 5‐HT₃ receptor antagonist
  Cancer, 2003
• The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group
  Journal of Clinical Oncology, 2003
• Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy‐induced nausea and vomiting
  Cancer, 2003
• Clinical Science Review: Comparative Review of 5-HT₃Receptor Antagonists in the Treatment of Acute Chemotherapy-Induced Nausea and Vomiting
  Cancer Investigation, 2000
• Potent inhibition of both the acute and delayed emetic responses to cisplatin in piglets treated with GR205171, a novel highly selective tachykinin NK₁ receptor antagonist
  British Journal of Pharmacology, 1998
• The anti‐emetic effects of CP‐99,994 in the ferret and the dog: role of the NK₁ receptor
  British Journal of Pharmacology, 1995
• Anti-emetic profile of a non-peptide neurokinin NK1 receptor antagonist, CP-99,994, in ferrets
  European Journal of Pharmacology, 1993
• On the receiving end—patient perception of the side-effects of cancer chemotherapy
  European Journal of Cancer and Clinical Oncology, 1983